Prostate Cancer

Prostate cancer patients who also have long-term diabetes mellitus and/or diabetes with organ failure may have a higher likelihood of developing more aggressive, poorly differentiated disease, new study data suggest.

The most recent data from the COU-AA-302 phase III trial support the efficacy and safety of abiraterone acetate (Zytiga) as a treatment for metastatic castration-resistant prostate cancer in men who are chemotherapy-naive.

The AUA has released a PSA-focused, evidence-based guideline on early detection of prostate cancer that is intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening, said H. Ballentine Carter, MD.

Drugs and devices in the pipeline from Medivation, Inc.; Astellas Pharma Inc.; TARIS Biomedical; Exelixis, Inc.; and Bioniche Life Sciences Inc.

A new closer look at genomes in prostate cancer has revealed that genetic mutations occur in abrupt, periodic bursts, causing complex, large-scale reshuffling of DNA driving the development of the disease.

Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, a recently published study found.

Incidence rates for prostate and other cancers are statistically higher than expected among World Trade Center rescue and recovery workers, according to a recent study.

Prostate cancer patients who also have long-term diabetes mellitus and/or diabetes with organ failure may have a higher likelihood of developing more aggressive, poorly differentiated prostate cancer, a new study suggests.

Researchers have shown, via a phase I trial, that the relationship between nerves and prostate cancer in perineural invasion is susceptible to therapeutic intervention with neurotoxic agents such as onabotulinumtoxinA (Botox).

Transrectal anterior zone sampling of the prostate may be a viable alternative to transperineal template biopsies in patients with negative previous biopsies and with rising PSA or persistently elevated PSA, researchers from the United Kingdom report.

African-American men eligible for active surveillance have a higher risk of advanced cancer on final surgical pathology compared to Caucasian men, suggesting the need for more stringent criteria for active surveillance for African-American men, according to a recently published study.

A single PSA test at 45 years of age may help predict long-term risk of developing aggressive prostate cancer, according to a recent study.

EDAP TMS said the FDA has provided a positive filing review notification on the company’s pre-market approval application for its Ablatherm Integrated Imaging HIFU (high-intensity focused ultrasound) device for the treatment of low-risk, localized prostate cancer.

New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.

Men with abnormal findings on digital rectal exam or other indicators of prostate cancer should be tested, but the evidence is insufficient to justify preferentially screening diabetic men because they may be at a higher risk of developing clinically significant prostate cancer.

New research on the downstream outcomes following PSA screening may help inform individualized decisions among older men considering screening.

Intermittent androgen deprivation therapy (ADT) may compromise survival for metastatic hormone-sensitive prostate cancer patients compared with continuous ADT, according to a recently published multicenter study.

More than half of prostate cancers detected by PSA measurement are intermediate or high risk at diagnosis, according to findings from a large, population-based study.

The American College of Physicians has become the latest organization to weigh in on the controversial subject of PSA screening for prostate cancer.

Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.

Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.

Increased adoption of the practice of obtaining 10- to 12-core biopsy specimens of the prostate has resulted in increased detection of prostate cancer across the United States, a recent large study shows.

Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, reported researchers from the University of Pennsylvania, Philadelphia.

Researchers at the University of Maryland have identified a peptide derived from Pacific cod that may inhibit prostate cancer and possibly other cancers from spreading.

Since the days of the digitally directed prostate nodule biopsy using the Vim-Silverman needle, the optimum prostate biopsy strategy has evolved.

The American Society for Radiation Oncology’s board of directors recently approved a statement regarding the use of proton beam therapy for prostate cancer, presumably due to recent reports suggesting the treatment provides little long-term benefit over traditional radiation despite its higher cost.

Anticoagulation while on docetaxel (Taxotere) chemotherapy appears to be an independent predictor of survival in men with metastatic castration-resistant prostate cancer (mCRPC).

Focal laser ablation is safe and can be performed without the troubling complications associated with more aggressive therapies for low-risk prostate cancer, results of a small phase I study indicate.

More stringent criteria may be needed for African-American men with prostate cancer when considering active surveillance for their disease, new research from The Cancer Institute of New Jersey, New Brunswick suggests.

Patients with high-risk prostate cancer who undergo 18 months of androgen blockade live as long as those who have 36 months of treatment, according to results of a recent phase III study.